# Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

> **NCT01466868** · PHASE2 · TERMINATED · sponsor: **Centre Leon Berard** · enrollment: 22 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** MK2206

## Key facts

- **NCT ID:** NCT01466868
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-09
- **Final completion:** 2014-06
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions
- **Last updated:** 2014-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466868, "Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01466868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*